Table 3.

Association of baseline rituximab use and each COVID-19 outcome with csDMARD as the referent category from US N3C cohort.

Primary Outcomes	Multivariable adjusted OR (95%CI)#
Hospitalization@	2.14 (1.51–3.04)
ICU admission	5.22 (1.77–15.41)
30-day mortality	1.12 (0.47–2.63)
Severe/fatal COVID-19 (WHO severity 7–10)*	1.66 (0.89–3.08)
Secondary Outcomes
Invasive ventilation	2.74 (1.36–5.51)
AKI in hospital	1.50 (0.80–2.82)
ICU mortality	2.43 (0.28–20.99)
In-hospital mortality	0.80 (0.42–1.80)
	Multivariable adjusted Beta Estimate (95% CI)
ICU LOS	2.35 (−11.33- 16.02)
Hospital LOS	3.22 (−0.32 −6.77)

Abbreviations: AKI: Acute kidney injury; CI: Confidence interval; csDMARD: conventional synthetic disease modifying anti-rheumatic drugs; ICU: Intensive care unit; LOS: Length of stay; OR: Odds Ratio.

^⁎COVID-19 severity definition used:

Mild: Outpatient World Health Organization (WHO) Severity 1–3

Mild-ED: Outpatient with Emergency department visit WHO Severity ∼3

Moderate: Hospitalized without invasive ventilation WHO Severity 4–6

Severe: Hospitalized with invasive ventilation or ECMO WHO Severity 7–9

Hospital Mortality or Discharge to Hospice WHO Severity 10.

^#Findings with p-values <0.05 are bolded in the table.

^@Hospitalization: adjusted for demographics, weight categories per BMI as normal vs. underweight, overweight, and obese, smoking status, US region, and modified Deyo-Charlson index.